REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM
Clinical trials for REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: targeted drug attacks gene flaw
Disease control OngoingThis study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…
Matched conditions: REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare cancers: drug targets tumor growth
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…
Matched conditions: REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Engineered immune cells injected directly into the brain take on childhood tumors
Disease control OngoingThis early-stage trial tests a new treatment called SC-CAR4BRAIN for children and young adults with certain aggressive brain tumors, including DIPG and DMG. The treatment involves taking a patient's own immune T cells, engineering them in a lab to recognize and attack tumor cells…
Matched conditions: REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC